No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, March 25, 2025 – ...

Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

(Repeats Feb 16 story with no changes to text) By Medha Singh and Manas Mishra (Reuters) - U.S.-based Eli Lilly (NYSE:LLY) and... By Medha Singh and Manas Mishra (Reuters) - U.S.-based Eli Lilly ...

Amidst a backdrop of global trade policy uncertainty and mixed economic signals, the European market has shown resilience, with Germany's DAX Index rising by over 2% despite broader concerns impacting ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...

Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF) to jointly develop an ...